{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Perez Stachowski J"],"funding":["Gilead Sciences (Spain)","Gilead Sciences"],"pagination":["4994"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9457350"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(17)"],"pubmed_abstract":["Objective: The primary endpoint of the study was to determine the proportion of patients with HIV RNA < 50 copies/mL at 48 weeks. Design: Phase IV, multicentric, open-label, single-arm clinical trial of participants recruited in 2018−2019 to evaluate the efficacy and safety of tenofovir alafenamide/emtricitabine/elvitegravir-cobicistat (TAF/FTC/EVG-c) as first-line treatment in HIV-1 infected naïve participants with advanced disease. Methods: Adverse events were graded according to the Division of AIDS scale version 2.0. Quantitative variables were recorded as median and interquartile range, and qualitative variables as absolute number and percentage. T-Student or Wilcoxon tests were used to analyze intragroup differences of the continuous variables. Results: Fifty participants were recrui"],"journal":["Journal of clinical medicine"],"pubmed_title":["Use of Tenofovir Alafenamide/Emtricitabine/Elvitegravir-Cobicistat in HIV-Naive Patients with Advanced Disease: GENIS Study."],"pmcid":["PMC9457350"],"funding_grant_id":["IN-ES-292-4051"],"pubmed_authors":["Ryan P","Nunez MJ","Dominguez M","Perez Stachowski J","Rial Crestelo D","Cabello N","Moreno Zamora A","Bisbal O","Vivancos Gallego MJ","Troya J","Espinosa Aguilera N","Sierra JO"],"additional_accession":[]},"is_claimable":false,"name":"Use of Tenofovir Alafenamide/Emtricitabine/Elvitegravir-Cobicistat in HIV-Naive Patients with Advanced Disease: GENIS Study.","description":"Objective: The primary endpoint of the study was to determine the proportion of patients with HIV RNA < 50 copies/mL at 48 weeks. Design: Phase IV, multicentric, open-label, single-arm clinical trial of participants recruited in 2018−2019 to evaluate the efficacy and safety of tenofovir alafenamide/emtricitabine/elvitegravir-cobicistat (TAF/FTC/EVG-c) as first-line treatment in HIV-1 infected naïve participants with advanced disease. Methods: Adverse events were graded according to the Division of AIDS scale version 2.0. Quantitative variables were recorded as median and interquartile range, and qualitative variables as absolute number and percentage. T-Student or Wilcoxon tests were used to analyze intragroup differences of the continuous variables. Results: Fifty participants were recrui","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2025-04-21T14:15:11.665Z","creation":"2025-04-21T14:15:11.665Z"},"accession":"S-EPMC9457350","cross_references":{"pubmed":["36078925"],"doi":["10.3390/jcm11174994"]}}